|
|
POB 12247
Jerusalem, 91121 Israel
phone:+972-545-245-677
fax:+972-2-642-9856 |
| Symbol |
Private |
| Founded |
2005 |
| Employees |
|
|
|
| www.cellcure.co.il
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Stem Cell Therapies for Degenerative Conditions |
|
| Management |
| Charles S. Irving, Ph.D., CEO; Prof. Benjamin Reubinoff, CSO and R&D activities director; |
|
|
| |
| Keywords |
| Neurology, Ophthalmology. Stem Cells, Age-Related Macular Degeneration (ARMD), Parkinson's Disease, Multiple Sclerosis |
|
|
|
|
|
| Description |
|
Cell Cure Neurosciences Ltd. (Cell Cure) is focused on the development of cell therapies for retinal and neural degenerative diseases. |
|
| Products / Services |
Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. Both of these cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company's OpRegen product is intended for use in RPE transplantations in patients with age related macular degeneration (ARMD) and is expected to be among the first hESC based products to reach clinical trials.
|
|
| Technology / Differentiation |
| Cell Cure's lead OpRegen cell therapy product utilizes two new technologies that address these concerns. First, Cell Cure uses a new method that drives the differentiation of human embryonic stem cells into RPE cells. These researchers have shown in a small animal model of AMD that RPE cells produced using this method can preserve vision when transplanted below the retina. Second, Cell Cure is utilizing a novel technology to produce ultrathin membranes of a biologically compatible material coated with a polarized monolayer of its hESC derived RPE cells. Over the next year, the company plans to test the cell membrane complex in a large animal model. Cell Cure's other cell therapy products under development include neural progenitor cells designed to replace the dopamine producing cells destroyed in Parkinson's disease (PD) and Cell Cure's NeurArrest neural cells that target in on and modulate the immune system's self-destruction of myelin coating of nerve cells in multiple sclerosis. |
|
| Market / Customers |
The dry form of AMD is the leading cause of visual impairment over the age of 55. There is no cure for ARMD at present; the most promising future therapy is the replacement of the layer of damaged RPE cells that support and nourish the retina.
|
|
| Status |
Anticipated milestones for Cell Cure in 2009-2010 include - Selection of the clinical grade hESCs as starting material
- Completion of the development of cryopreservation methods for RPE cells
- Successful in vitro testing of RPE cells bound to a biocompatible membrane
- Demonstration of safety and efficacy in a porcine animal model
- Start of production of clinical grade cells for clinical trials
As soon as proof of concept is obtained in the large animal study, the production of clinical grade cells for use in clinical trials will begin. The company will continue on a limited basis its development work on neural progenitor cells intended for use in Parkinson's disease and multiple sclerosis. The achievement of these goals depends on new funding.
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
